कोशिश गोल्ड - मुक्त

BHARAT EYES GLOBAL BIOMANUFACTURING DOMINANCE: Boosting Innovation, Collaboration & Entrepreneurship with BioE3 Policy

Bio Spectrum

|

BioSpectrum India Oct 2024

Bharat has demonstrated a strong economic growth in the past decade and is poised to be amongst the global leaders in the next industrial revolution by leveraging emerging technologies and new innovative solutions.

BHARAT EYES GLOBAL BIOMANUFACTURING DOMINANCE: Boosting Innovation, Collaboration & Entrepreneurship with BioE3 Policy

Bharat is competitively positioned to be amongst the global leaders in futuristic manufacturing that leverages living systems. Biomanufacturing can fundamentally transform the global economy from today's consumptive manufacturing paradigm to the one based on regenerative principles. Biomanufacturing refers to the use of engineered microbial, plant, and animal (including human) cells with increasing precision and control to produce commercially important products on scale. These are versatile processes that have the potential to create bio-based products allowing efficient utilisation of resources, in a scalable and costeffective manner with reduced environmental impact. Keeping in view the national priority of steering Bharat on the path of accelerated 'Green Growth', an integrated BioE3 (Biotechnology for Economy, Environment and Employment) Policy for "Fostering High-Performance Biomanufacturing" with an aim to make a green, clean, prosperous, and self-reliant Bharat was released on September 12 at Global Bio-India (GBI) 2024. Let's take a look at how the BioE3 Policy for biomanufacturing is set to transform this landscape.

Bharat's bioeconomy is estimated to be valued around $300 billion by 2030, making it the third largest biotech destination in Asia Pacific and one of the top biotech destinations globally. With COVID-19 providing the industry with a much-needed boost, the country's bioeconomy reached $151 billion in 2023 and witnessed an exponential increase in valuation over the previous 11 years. As one of the top hubs for bioinnovation and biomanufacturing today, Bharat is recognised as a rising sector and a crucial component of the country's economic growth plan, which aims to see its GDP grow to $5 trillion by 2027.

Bio Spectrum से और कहानियाँ

Bio Spectrum

Bio Spectrum

WHO certifies Suriname malaria-free

Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation

Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.

time to read

1 min

August 2025

Bio Spectrum

Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab

Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.

time to read

1 min

August 2025

Bio Spectrum

Illumina buys SomaLogic for $425 M to accelerate proteomics business

Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26

Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.

time to read

1 min

August 2025

Bio Spectrum

WHO highlights risks associated with use of semaglutide medicines

The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin

Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru

AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Novo Nordisk launches injectable Semaglutide for weight management in India

Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?

India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.

time to read

12 mins

August 2025

Listen

Translate

Share

-
+

Change font size